|
|
5-day change | 1st Jan Change | ||
|
3,536.00 JPY |
+0.37% | +11.09% | -18.73% | |
April 27, 2025 at 11:44 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Daiichi Sankyo Co Ltd – To Buy Back Up To 4.29% Of Own Shares Worth 200 Billion Yen |
Apr. 25 |
RE |
|
Daiichi Sankyo Company, Limited announces an Equity Buyback for 80,000,000 shares, representing 4.29% for ¥200,000 million. |
Apr. 25 |
CI |
|
Daiichi Sankyo Company, Limited authorizes a Buyback Plan. |
Apr. 24 |
CI |
|
European Equities Closed for Easter Monday; EU Reminds Tech Giants it Will Enforce Digital Rules |
Apr. 21 |
MT |
|
Sector Update: Health Care Stocks Fall Pre-Bell Monday |
Apr. 21 |
MT |
|
AstraZeneca Says Breast Cancer Combination Therapy Shows Improvement in Progression-Free Survival |
Apr. 21 |
MT |
|
AstraZeneca, Daiichi Sankyo’s Breast Cancer Drug Shows High-level Results in Late-stage Trial |
Apr. 21 |
MT |
|
Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer |
Apr. 21 |
CI |
|
Wayfinder Biosciences And Daiichi Sankyo Collaborate To Develop Novel Rna-Targeting Therapies For Neurodegenerative Disease |
Apr. 15 |
RE |
|
Trump’s tariffs and threatened trade actions |
Apr. 14 |
RE |
|
Trump’s tariffs and threatened trade actions |
Apr. 14 |
RE |
|
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs — Update |
Apr. 09 |
DJ |
|
London stocks remain red as gilt yields surge |
Apr. 09 |
AN |
|
UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo’s Cancer Drug Enhertu |
Apr. 09 |
MT |
|
Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines |
Apr. 09 |
DJ |
|
Daiichi Sankyo and AstraZeneca secure EU approval for Datroway |
Apr. 09 |
AN |
|
Tranche Update on Daiichi Sankyo Company, Limited’s Equity Buyback Plan announced on February 28, 2025. |
Apr. 08 |
CI |
|
AstraZeneca: first approval in Europe for Datroway |
Apr. 08 |
CF |
|
Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer |
Apr. 08 |
CI |
|
Daiichi Sankyo Company, Limited’s Equity Buyback announced on February 28, 2025, has closed with 13,971,600 shares, representing 0.74% for ¥49,999.9 million. |
Apr. 07 |
CI |
|
Trump’s tariffs and threatened trade actions |
Apr. 07 |
RE |
|
AstraZeneca gets EU approval for cancer treatments Enhertu and Imfinzi |
Apr. 04 |
AN |
|
AstraZeneca: EU approves Enhertu in breast cancer |
Apr. 04 |
CF |
|
BP Chair to step down; AstraZeneca touts EU approval |
Apr. 04 |
AN |
|
AstraZeneca, Daiichi Sankyo Obtain EU Approval for Enhertu as Breast Cancer Treatment |
Apr. 04 |
MT |
4568: Dynamic Chart
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.
More about the company
Buy
Last Close Price
3,523.00JPY
Average target price
5,936.11JPY
Spread / Average Target
+68.50%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
